CES 2026: GIGABYTE is “AI Forward,” Showcasing AI Factory, Physical AI, and Agentic AI Solutions
GIGABYTE Technology, a global leader known for its engineering excellence in high-performance computing and AI servers, continues to strengthen its position as one of Taiwan’s most AI-centric server innovators. At CES 2026, GIGABYTE is to present its complete computing ecosystem under the theme “AI Forward”—highlighting how its technologies form the computational backbone of next-generation AI infrastructure, supporting AI development across cloud, edge, and personal devices, and full-stack solutions enabling organizations to deploy AI with greater speed, scale, and efficiency.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251224890815/en/
CES 2026: GIGABYTE is “AI Forward,” Showcasing AI Factory, Physical AI, and Agentic AI Solutions
Build Future-Ready AI Factory
GIGABYTE introduces its one-stop AI data center solution with GIGAPOD, a modular “Building-Block Design” that integrates high-performance servers, high-speed networking, and GIGABYTE POD Manager (GPM) software, streamlining AI infrastructure design, deployment, and validation—accelerating the creation of enterprise AI Factories.
At the core, GIGAPOD deploys G4L4/G4L3 direct-liquid-cooling servers supporting Intel® Xeon® 6 processors and based on NVIDIA HGX B300 systems, and AMD EPYC™ 9005/9004 processors with AMD Instinct™ MI355X accelerators. These servers balance extreme compute density with advanced thermal efficiency. In addition, GIGABYTE introduces an in-house Rack Management Switch that centralizes management for up to eight DLC racks within a compact 1U form factor. It supports multi-vendor CDU communication protocols and precise leak detection, significantly enhancing system reliability and management efficiency—establishing a new benchmark for intelligent, scalable AI data centers.
GIGABYTE further expands its server families for data centers at all scales. The flagship NVIDIA Grace Blackwell Ultra NVL72—a rack-level compute node with 72 NVIDIA Grace CPUs, complemented by NVIDIA Quantum-X800 InfiniBand and NVIDIA Spectrum-X Ethernet networking, can deliver up to 50× inference performance compared with the previous NVIDIA Hopper generation.
For training, simulation and high-volume inference, GIGABYTE presents the G894-SD3-AAX7 and XL44-SX2-AAS1 supercomputers, accelerated by NVIDIA HGX B300 and NVIDIA RTX PRO™ 6000 Blackwell Server Edition GPUs respectively. Both are equipped with dual Intel® Xeon® 6 processors, DDR5 memory, and high-speed InfiniBand/Ethernet connectivity, while integrating NVIDIA BlueField-3 DPUs to enhance data security and computational efficiency. The W775-V10-L01 workstation brings server-class GPU performance and closed-loop liquid cooling to creators and small enterprises deploying on-prem AI workflows.
Compact Edge Solutions for Physical AI
GIGABYTE extends AI from data centers to real-world operations through its embedded systems and industrial PCs—built for environments where low latency, reliability, and 24/7 edge inference are critical. At CES, this vision takes shape through a smart warehouse showcase featuring:
- compact edge computers for high TOPS AI inference,
- low-power embedded systems for AGV/AMR fleet coordination,
- industrial PCs for robotic arms and conveyor systems, and
- versatile designs with rich I/O for sensors and machine vision.
These solutions enable AI to think and act where data is created, marking a key step toward Physical AI.
Shape Everyday AI Agent
As the world enters the era of Agentic AI, GIGABYTE introduces the AI TOP series, the AI TOP ATOM, AI TOP 100 Z890, and AI TOP 500 TRX50, premium AI-empowered desktop computers that enable local LLM/LMM inference, fine-tuning, and RAG applications using standard electrical systems, ensuring private, secure, and affordable computing. Beyond exceptional hardware, GIGABYTE also introduces the AI TOP Utility software, which simplifies setup, offers an intuitive interface, and streamlines AI workflows for model management and deployment.
GIGABYTE also expands AI-optimized client computing with laptops integrated with the GiMATE AI companion, delivering on-device assistance for creators and professionals. The new AORUS RTX 5090 AI BOX, featuring Thunderbolt™ 5 connectivity and the GeForce RTX™ 5090 GPU, enables notebook users to access near-desktop AI and graphics performance.
LVCC North Hall, Booth #8519
https://www.gigabyte.com/Events/CES
View source version on businesswire.com: https://www.businesswire.com/news/home/20251224890815/en/
Contacts
Michael Pao brand@GIGABYTE.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom